Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Widely referenced in preclinical literature for its interaction with VEGF, FAK-paxillin, and nitric oxide pathways
We keep our process simple: provide dependable research materials, communicate openly, and stand behind what we offer.
For beginners or anyone prioritizing accuracy, the 1.5mL or 3.0mL options are safer choices
Offer a non-stimulant alternative to traditional weight loss medications
Many patients use LIPO-B to complement GLP-1 therapy
DOI: 10.3390/ijms19071987 BPC-157 angiogenic signaling VEGFR2-Akt-eNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860 TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: PubMed 12581423 TB-4 Ac-SDKP anti-fibrotic fragment N-terminal tetrapeptide (fragment 14) released by meprin- and POP processing
